We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-1.03 | -1.06% | 96.47 | 97.47 | 96.85 | 97.21 | 1,426,052 | 01:00:00 |
By Denise Roland
GlaxoSmithKline PLC swung to a net loss in the fourth quarter of the year even as revenue increased, largely due to restructuring costs following its three-part transaction with Novartis AG.
The U.K.-based drugmaker said its loss attributable to shareholders was GBP354 million ($510 million) in the quarter ending Dec. 31, compared with a GBP1 billion profit a year earlier, while revenue climbed to GBP6.3 billion from GBP6.2 billion. Core net profit, which strips out some one-time items, fell 34% to GBP874 million. Analysts had expected revenue of GBP6.3 billion and core net profit of GBP903 million.
The decline in core net profit was largely down to Glaxo's shift to a higher-volume, lower-margin business following its $20 billion asset-swap deal with Novartis. In that deal, which closed in the first quarter of 2015, Glaxo traded its cancer drugs for the Swiss company's vaccines business. The pair also formed a joint venture for their consumer health care businesses which span over-the-counter drugs, such as painkiller Panadol, as well as non-pharmaceuticals like toothpaste.
Write to Denise Roland at Denise.Roland@wsj.com
(END) Dow Jones Newswires
February 03, 2016 08:08 ET (13:08 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions